创伤性脑损伤后30分钟和60分钟内GFAP、UCH-L1和MAP-2的诊断效能
该研究为多中心院前TBI队列(20个中心、39个急救医疗服务系统,2015年5月至2017年3月)的生物标志物分析,纳入血流动力学稳定的成人可疑中重度TBI患者,检测伤后30分钟和60分钟内血GFAP、UCH-L1、MAP-2,评估其识别CT颅内病变、24小时内神经外科干预(NSI)和7天内临床重要早期结局(CIEO)的效能。伤后30分钟内采血者中,GFAP对CT病变的AUC最高(0.88),其次为MAP-2(0.78)和UCH-L1(0.75);60分钟内采血者AUC分别为GFAP 0.89、MAP-2 0.76、UCH-L1 0.73。GFAP在30分钟内以30 pg/mL为界,对CT病变敏感度98.1%、特异度34.4%;GFAP>6200 pg/mL与NSI和CIEO高风险相关。联合检测不优于GFAP单用,GFAP是与所有结局相关的最强独立标志物。
要点
- 伤后30分钟内采血,GFAP对CT颅内病变的AUC为0.88(95%CI 0.85-0.92),高于MAP-2的0.78(0.73-0.83)和UCH-L1的0.75(0.70-0.80)。
- 伤后60分钟内采血,GFAP对CT病变的AUC为0.89(95%CI 0.86-0.92),MAP-2为0.76(0.72-0.80),UCH-L1为0.73(0.69-0.77)。
- 伤后30分钟内GFAP以30 pg/mL为界,对CT病变敏感度98.1%(95%CI 94.9%-99.4%)、特异度34.4%(95%CI 27.2%-42.2%)。
- GFAP>6200 pg/mL与24小时内NSI和7天内CIEO高风险相关。
- 三种标志物联合检测对任何结局均不优于GFAP单用;GFAP是与所有结局相关的最强独立标志物。
适用人群与场景
- 多中心院前TBI队列中血流动力学稳定的成人创伤患者,疑似中重度TBI,来自北美20个中心和39个急救医疗服务系统,2015年5月至2017年3月纳入。
- 共966例入组,804例有血样,其中563例在伤后60分钟内采血、375例在伤后30分钟内采血。
诊断标准与关键阈值
- 伤后30分钟内GFAP以30 pg/mL为界,对CT颅内病变的敏感度98.1%(95%CI 94.9%-99.4%)、特异度34.4%(95%CI 27.2%-42.2%)。
- GFAP>6200 pg/mL与24小时内NSI和7天内CIEO高风险相关。
研究设计与关键结果
- 研究类型为多中心院前TBI队列的生物标志物分析,来自Prehospital Tranexamic Acid Use for TBI临床试验,覆盖北美20个中心和39个急救医疗服务系统,2015年5月至2017年3月。
- 804例有血样患者平均(SD)年龄41(19)岁,418例(74.2%)为男性;563例在伤后60分钟内采血,375例在伤后30分钟内采血。
- 伤后30分钟内采血者中,212例(56.5%)有CT病变,61例(16.3%)发生NSI,112例(30.0%)发生CIEO。
- 伤后60分钟内采血者中,316例(56.1%)有CT病变,95例(16.9%)发生NSI,172例(30.6%)发生CIEO。
- 所有标志物在伤后30分钟和60分钟内均随CT弥漫性损伤加重而显著升高。
- 伤后30分钟内采血,GFAP对CT病变的AUC最高,为0.88(95%CI 0.85-0.92),MAP-2为0.78(95%CI 0.73-0.83),UCH-L1为0.75(95%CI 0.70-0.80)。
- 伤后60分钟内采血,GFAP对CT病变的AUC为0.89(95%CI 0.86-0.92),MAP-2为0.76(95%CI 0.72-0.80),UCH-L1为0.73(95%CI 0.69-0.77)。
- 伤后30分钟内采血,对NSI的AUC:GFAP 0.78(95%CI 0.72-0.84)、MAP-2 0.75(95%CI 0.68-0.81)、UCH-L1 0.69(95%CI 0.63-0.75);对CIEO的AUC:GFAP 0.89(95%CI 0.85-0.93)、MAP-2 0.83(95%CI 0.78-0.87)、UCH-L1 0.77(95%CI 0.72-0.82)。
证据类型、等级与局限
- 证据类型:多中心院前TBI队列的生物标志物分析(队列研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,本研究为GFAP在伤后最初30分钟内的早期应用奠定了基础,可供未来临床和研究工作参考。
- 院前中重度TBI患者伤后30分钟内血GFAP对CT颅内病变的AUC为0.88,以30 pg/mL为界敏感度98.1%、特异度34.4%。
- GFAP>6200 pg/mL与24小时内NSI和7天内CIEO高风险相关。
- 联合检测三种标志物对所有结局均不优于GFAP单用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Data on the performance of traumatic brain injury (TBI) biomarkers within minutes of injury are lacking.
OBJECTIVES: To examine the performance of glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and microtubule-associated protein 2 (MAP-2) within 30 and 60 minutes of TBI in identifying intracranial lesions on computed tomography (CT) scan, need for neurosurgical intervention (NSI), and clinically important early outcomes (CIEO).
DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a biomarker analysis of a multicenter prehospital TBI cohort from the Prehospital Tranexamic Acid Use for TBI clinical trial conducted across 20 centers and 39 emergency medical systems in North America from May 2015 to March 2017. Prehospital hemodynamically stable adult patients with traumatic injury and suspected moderate to severe TBI were included. Blood samples were measured for GFAP, UCH-L1, and MAP-2. Data were analyzed from December 1, 2023, to March 15, 2024.
MAIN OUTCOMES AND MEASURES: The presence of CT lesions, diffuse injury severity on CT, NSI within 24 hours of injury, and CIEO (composite outcome including early death, neurosurgery, or prolonged mechanical ventilation ≥7 days) within 7 days of injury.
RESULTS: Of 966 patients enrolled, 804 patients (mean [SD] age, 41 [19] years; 418 [74.2%] male) had blood samples, including 563 within 60 minutes and 375 within 30 minutes of injury. Among patients with blood drawn within 30 minutes of injury, 212 patients (56.5%) had CT lesions, 61 patients (16.3%) had NSI, and 112 patients (30.0%) had CIEO. Among those with blood drawn within 60 minutes, 316 patients (56.1%) had CT lesions, 95 patients (16.9%) had NSI, and 172 patients (30.6%) had CIEO. All biomarkers showed significant elevations with worsening diffuse injury on CT within 30 and 60 minutes of injury. Among blood samples taken within 30 minutes, GFAP had the highest area under the receiver operating characteristic curve (AUC) to detect CT lesions, at 0.88 (95% CI, 0.85-0.92), followed by MAP-2 (AUC, 0.78; 95% CI, 0.73-0.83) and UCH-L1 (AUC, 0.75; 95% CI, 0.70-0.80). Among blood samples taken within 60 minutes, AUCs for CT lesions were 0.89 (95% CI, 0.86-0.92) for GFAP, 0.76 (95% CI, 0.72-0.80) for MAP-2, and 0.73 (95% CI, 0.69-0.77) for UCH-L1. Among blood samples taken within 30 minutes, AUCs for NSI were 0.78 (95% CI, 0.72-0.84) for GFAP, 0.75 (95% CI, 0.68-0.81) for MAP-2, and 0.69 (95% CI, 0.63-0.75) for UCH-L1; and for CIEO, AUCs were 0.89 (95% CI, 0.85-0.93) for GFAP, 0.83 (95% CI, 0.78-0.87) for MAP-2, and 0.77 (95% CI, 0.72-0.82) for UCH-L1. Combining the biomarkers was no better than GFAP alone for all outcomes. At GFAP of 30 pg/mL within 30 minutes, sensitivity for CT lesions was 98.1% (95% CI, 94.9%-99.4%) and specificity was 34.4% (95% CI, 27.2%-42.2%). GFAP levels greater than 6200 pg/mL were associated with high risk of NSI and CIEO.
CONCLUSIONS AND RELEVANCE: In this cohort study of prehospital patients with TBI, GFAP, UCH-L1, and MAP-2 measured within 30 and 60 minutes of injury were significantly associated with traumatic intracranial lesions and diffuse injury severity on CT scan, 24-hour NSI, and 7-day CIEO. GFAP was the strongest independent marker associated with all outcomes. This study sets a precedent for the early utility of GFAP in the first 30 minutes from injury in future clinical and research endeavors.
参考来源
- Papa L, McKinley WI, Valadka AB, et al. Diagnostic Performance of GFAP, UCH-L1, and MAP-2 Within 30 and 60 Minutes of Traumatic Brain Injury. JAMA Netw Open. 2024. PMID: 39230905. doi:10.1001/jamanetworkopen.2024.31115
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。